<?xml version="1.0" encoding="UTF-8" ?><dbgapss xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbgapssws.1.0.xsd"><Study uid="46941" whole_study_id="46941" phs="002941" v="1" p="1" createDate="2022-04-12T14:29:31-05:00" completedByGPADate="2022-04-12T14:45:05-05:00" modDate="2022-06-06T15:24:22-05:00" maxParentChildStudyModDate="2022-06-06T15:24:22-05:00" num_participants="375"><StudyInfo accession="phs002941.v1.p1" parentAccession="phs002941.v1.p1"><StudyNameEntrez>CALGB/SWOG 80405 ct DNA Biomarker Evaluation</StudyNameEntrez><StudyTypes2 calculated="No"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="whole_targ_genome"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="Yes"><StudyType22 name="tumor_normal"/></StudyType21><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>sra</StudyType></StudyTypes><SraStorages><SraStorage location="NCBI"/></SraStorages></StudyInfo><Authority><ICs><IC id="4" name="NCI" is_funding_ic="true" is_admin_ic="true" primary="true"/></ICs><Persons><Person nedid="QU_GNE" aid="2" auth="eRA" login="QU_GNE" fname="Xueping" mname="" lname="Qu" email="xuepingq@gene.com"><Role allow_direct_access="true">PI</Role><Organization>GENENTECH, INC.</Organization></Person><Person nedid="0011263528" aid="1" auth="cit" login="mooneym" fname="Margaret" mname="Marian" lname="Mooney" email="mm723k@nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="DIYADAS" aid="2" auth="eRA" login="DIYADAS" fname="Diya" mname="" lname="Das" email="das.diya@gene.com"><Role>PI_ASSIST</Role><Organization>UNIVERSITY OF CALIFORNIA BERKELEYGENENTECH, INC.</Organization></Person><Person nedid="CHU.LIEN_GNE" aid="2" auth="eRA" login="CHU.LIEN_GNE" fname="Lien" mname="" lname="Chu" email="chu.lien@gene.com"><Role>TRP_SUB</Role><Organization>GENENTECH, INC.</Organization></Person><Person nedid="0011059039" aid="1" auth="cit" login="withersk" fname="Kim" mname="Juanita" lname="Witherspoon" email="kw265c@nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>Samples for this analysis were collected from the CALGB/SWOG 80405 trial, which was a phase III trial designed to determine whether the addition of cetuximab compared to bevacizumab to chemotherapies was superior as first-line treatment in advanced or metastatic CRC. The study design, patient eligibility, and clinical outcome of this trial have been reported previously. The CALGB 80405 trial was supported by National Cancer Institute grants U10CA180821, U10CA180882 and U24CA196171 (Alliance for Clinical Trials in Oncology), U10CA180790 (Mayo Clinic), U10CA180791 (Memorial Sloan Kettering), 10CA180795 (Indiana University), U10CA180799 (University of Wisconsin), U10CA180830 (University of Southern California Norris Cancer Hospital), U10CA180836 (The University of Chicago), U10CA180838 (The University of North Carolina), U10CA180850 (The Ohio State University), U10CA180867 (Dana-Farber Cancer Institute), and U10CA180888 (SWOG). P30CA014089, UG1CA180830, UG1CA233253, UG1CA233327, UG1CA233373, U10CA180820 (ECOG-ACRIN). The trial was also supported in part by Bristol-Myers Squibb, Eli Lilly, Genentech, Pfizer, and Sanofi. We thank the CALGB80405 team and the patients participating in this trial. We thank all members of our group for valuable suggestions, critical review of the data and the manuscript, including Carin Espenschied at Guardant Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. https://acknowledgments.alliancefound.org.</acknowledgement_statement><ic_specific_access_term/><DUC><File uri="dbgapssws.cgi?blob_id=46947&amp;file=get&amp;page=file" filename="dbGaP NCI CTEP DUCA Qu 4 11 22.pdf" md5="e8d9320c535c0f8a604f1ca20a5b8724" size="425561" modDate="2022-04-12T14:42:41-05:00" content-type="application/pdf"/></DUC><DUC_PDF><File uri="dbgapssws.cgi?blob_id=46947&amp;file=get&amp;page=file" filename="dbGaP NCI CTEP DUCA Qu 4 11 22.pdf" md5="e8d9320c535c0f8a604f1ca20a5b8724" size="425561" modDate="2022-04-12T14:42:41-05:00" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="contr_access" gsr_mode_label="Controlled-access (GSR are sensitive according to the Institutional Certification)"/><ConsentGroup uid="5174" CGType="cg_class_GRU" title="General Research Use (COL)" name="GRU-COL" dac_uid="59" dac_name="NCI DAC" irb-approval-required="No" collaboration-required="Yes"><Use-Restriction>Use of the data is limited only by the terms of the model Data Use Certification.
Requestor must provide a letter of collaboration with the primary study investigator(s).

The letter of collaboration for this study is the CTEP Notification e-mail described in the &#8220;CTEP CRADA Collaborator Review Process,&#8221; which can found at the end of the dataset's Data Use Certification Agreement (see dbGaP study page). The &#8220;CTEP CRADA Collaborator Review Process&#8221; describes the process and timeline for DAC review, and also includes a template for the CTEP notification e-mail. Requestor must first send a CTEP Notification e-mail to NCICTEPDAR@mail.nih.gov, and then upload a copy of this e-mail as part of their data access request for this dataset. Please review the &#8220;CTEP CRADA Collaborator Review Process&#8221; carefully to understand the additional terms for this dataset, and contact NCICTEPDAR@mail.nih.gov or NCIDAC@mail.nih.gov regarding any questions.</Use-Restriction></ConsentGroup><ConsentGroup uid="5175" CGType="cg_class_DS" title="Disease-Specific (Cancer, COL)" name="DS-CA-COL" dac_uid="59" dac_name="NCI DAC" irb-approval-required="No" collaboration-required="Yes"><Use-Restriction>Use of the data must be related to Cancer.
Requestor must provide a letter of collaboration with the primary study investigator(s).

The letter of collaboration for this study is the CTEP Notification e-mail described in the &#8220;CTEP CRADA Collaborator Review Process,&#8221; which can found at the end of the dataset's Data Use Certification Agreement (see dbGaP study page). The &#8220;CTEP CRADA Collaborator Review Process&#8221; describes the process and timeline for DAC review, and also includes a template for the CTEP notification e-mail. Requestor must first send a CTEP Notification e-mail to NCICTEPDAR@mail.nih.gov, and then upload a copy of this e-mail as part of their data access request for this dataset. Please review the &#8220;CTEP CRADA Collaborator Review Process&#8221; carefully to understand the additional terms for this dataset, and contact NCICTEPDAR@mail.nih.gov or NCIDAC@mail.nih.gov regarding any questions.</Use-Restriction></ConsentGroup><AdditionalEmails><Email>NCICTEPDAR@mail.nih.gov</Email></AdditionalEmails><TrustedPartners><TrustedPartner trp_id="3" trp_db_name="NCI Genomic Data Commons (GDC)" trp_download_url="https://gdc.cancer.gov" trp_help_url="support@nci-gdc.datacommons.io"><StudyFlags seq_data_to_ncbi="Yes" gen_phen_to_ncbi="Yes" has_out_ncbi_data="No"/></TrustedPartner></TrustedPartners></Policy><SRA/><Documents/><Status uid="14" name="completed_by_gpa" title="Completed by GPA"/></Study></dbgapss>